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Objective: Studies using animal models are important in drug development, but often poorly predict
treatment results in man. We investigated factors that may impact on the magnitude of the analgesic
treatment effect in animal models of osteoarthritis (OA) pain.
Design: Systematic review of studies that measured behavioural pain outcomes in small animal models of
OA, and tested drugs which reduce OA pain in man. Standardised mean difference (SMD) and 95% conﬁ-
dence intervals (CIs) were calculated using random effects meta-analysis for selected models and drugs.
Results: Most studies used rat models (42/50) and chemical methods of OA induction (39/50). Analgesic
treatment effect (SMD) was most commonly measured between drug- and vehicle treated rats with knee
OA. Meta-analysis was carried out for 102 such comparisons from 26 studies. The pooled SMD was 1.36
(95% CI ¼ 1.15e1.57). Non-steroidal anti-inﬂammatory drugs (NSAIDs) were associated with smaller
SMDs than opioids (z ¼ 3.25, P ¼ 0.001). Grip strength gave larger SMDs than assessment of static
weight bearing (z ¼ 4.60, P < 0.001), mechanically-evoked pain (z ¼ 3.83, P ¼ 0.001) and movement-
evoked pain (z ¼ 5.23, P < 0.001), and SMDs for mechanically-evoked pain were larger than for
movement-evoked pain (z ¼ 2.78, P ¼ 0.006). Studies that reported structural evaluation of OA
phenotype were associated with smaller SMDs (z ¼ 2.45, P ¼ 0.014). Publication was signiﬁcantly
biased towards positive ﬁndings.
Conclusion: Attention to study-level moderators and publication bias may improve the ability of research
using animal models to predict whether analgesic agents will reduce arthritis pain in man.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Arthritis pain results from complex interactions between joint
damage and inﬂammation, and abnormalities of pain processing1e3.
Analgesic drugs commonly prescribed for arthritis target a variety of
pain mechanisms, but may fail to provide adequate pain relief, or
may be discontinued due to adverse events4. There is an urgent need
to develop better analgesic drugs for people with arthritis.
Preclinical testing is an essential part of drug development and
licensing, and small animal models of osteoarthritis (OA)5,6 are
commonly used for developing treatments for arthritis pain.
However, animal models of OA have displayed relatively low.K. Suokas, Arthritis Research
ences Building, City Hospital,
ax: 44-(0)115-823-1757.
. Suokas).
ternational. Published by Elsevier Lspeciﬁcity for predicting analgesic agents that will reduce OA pain
in man, and several drugs that have shown promise in preclinical
studies have failed to fulﬁl that promise in clinical trials7,8. Such
failures are not exclusive to drug discovery for musculoskeletal pain
as evidenced by systematic reviews9e11 which have identiﬁed
methodology and quality as major factors inﬂuencing study out-
comes in preclinical studies. One of the key conclusions is that bias
caused by design and quality factors, together with a tendency to
publish only positive results, leads to an overestimation of drug
efﬁcacy. Low speciﬁcity in preclinical studies results in wasted re-
sources on unsuccessful clinical trials, and unnecessary participant
exposure to experimental drugs with uncertain toxicity. A better
understanding of factors that contribute to overestimation of
analgesic effects in preclinical studies should facilitate the devel-
opment of novel effective treatments for arthritis pain in the future.
We have undertaken a systematic review and meta-analysis to
examine heterogeneity across preclinical studies of pharmacologicaltd. All rights reserved.
Table I
The modalities, test methods and the outcome measures included in the review
Modality Test method Outcome measures
1. Thermally
evoked
pain
Hot plate; a radiant
heat source
Withdrawal latency
Acetone cooling test Flinching, shaking or toe-biting
Cold plate Withdrawal latency
2. Mechanically
evoked pain
Von Frey Withdrawal threshold or latency
Pressure Withdrawal threshold; vocalisation;
struggle
3. Movement
evoked pain
Gait analysis Duty cycle; swing phase; swing
speed; paw print intensity; stance;
propulsion; limb idleness; speed
Forced ambulation
(rod)
Use of the limb and presence of
a limp
Forced exercise Slips
Knee ﬂexions and/or
extensions
Vocalisation; struggle
4. Grip strength Grip strength The maximum force displayed by
an animal
5. Static weight
bearing
Incapacitance testing Hind paw weight distribution
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impact of study methodology and quality on the magnitude of the
observed analgesic treatment effect. A secondary aimwas to identify
suitable methodology to enable meta-analysis of preclinical studies
without unnecessary loss of relevant data, despite the use of diverse
pain-related behavioural tests across different stages of disease
progression. This is, to our knowledge, the ﬁrst meta-analysis of
preclinical studies of the effects of interventions inmodels of OApain.
Methods
Search strategy and selection of studies
Four bibliographic databases (Medline 1948-, Embase 1980-,
PubMed 1950- andWeb of Science 1970-) were searched to identify
studies published before July 2013. A systematic search strategy
without language restrictions was developed in Medline (Appendix
1) and replicated in the other databases. The search strategy com-
bined terms for OA, nociception, small animal models (i.e., the
species), and models of OA induction (spontaneous or chemically
induced or surgically induced). The review was limited to small
animal models because investigation of disease mechanisms and
initial screening of therapeutics typically involve small animals
(mice, rats, guinea pigs, and rabbits) due to a faster disease pro-
gression, lower cost and ease of handling5,6. Reports were down-
loaded into Endnote X4 (Thomson Reuters, USA).
Studies were eligible for inclusion if they reported the ﬁndings
in a full paper published in a peer-reviewed academic journal and
involved: (1) a prospective controlled experiment using mice, rats,
Guinea pigs, or rabbits; (2) a treatment group with spontaneous or
experimentally-induced OA; (3) a matched control group of ani-
mals with OA, sham-operated or vehicle-injected or naive animals;
(4) testing the analgesic treatment effect of a drug from a class of
pharmacological interventions recommended in the National
Institute for Health and Care Excellence (NICE) guideline for OA
pain12: oral non-steroidal anti-inﬂammatory drugs (NSAIDs)
including COX-2 inhibitors; paracetamol; opioids; intra-articular
corticosteroid injections; topical NSAIDs; and topical capsaicin;
(5) at least one of following pain-related behavioural test modal-
ities (i.e., pain modalities): thermally-evoked pain; mechanically-
evoked pain; movement-evoked pain; grip strength; and static
weight bearing (Table I).
Abstracts were assessed by AKS and DRS, and full text was
retrieved for all potentially relevant studies. Full papers were
assessed to identify the species; OA models; treatment and
control groups; drugs; and the pain modalities used in the
studies. The meta-analysis was limited to a sub-group of studies
to reduce heterogeneity among the experimental material.
Firstly, the analysis was carried out on studies that compared
drug- and vehicle-treated groups of rats with OA of the knee that
is the most commonly investigated joint in OA models13. Sec-
ondly, only drugs tested in at least three studies using a systemic
route of administration (oral, intravenous, subcutaneous, intra-
muscular) were included. Finally, studies were only included if
they reported (either numerically or in a graph) the mean values
and estimates of random variability for analgesic treatment effect
at individual time points. Additional data on sample sizes were
requested from the authors, if they were not reported fully in the
papers14e17.
Data extraction
Data were extracted for study design including: experimental
models of OA (spontaneous; chemical substance and dose; sur-
gical method to induce OA); sample size per treatment andcontrol group; strain, sex, age and weight of the animals; pain
modalities; test methods; outcome measures; the drug and its
dose, route, and date(s) of administration after the induction of
OA; date(s) of outcome measurement after the induction of OA;
and time to outcome measurement after the administration of
the drug.
If a study involved more than one comparison (for different
drugs, doses, times points and/or outcome measures) data were
extracted separately from each. Where data were presented only
graphically, the mean values and estimates of random variability
(standard error (SE) or standard deviation (SD)) for pain-related
behavioural outcome measures were extracted using digital ruler
software (Plot Digitizer 1.9, University of South Alabama, USA).
Digital ruler software enabled the measurement of distances, areas
and perimeters of ﬁgures on a computer screen18,19. In line charts
where the indicator lines for a speciﬁc time point were overlapping
and difﬁcult to read, SEs/SDs were extracted by reading the line
with the highest estimate of variability.
Data were extracted and coded by one reviewer (AKS), and a
sub-set of key variables was validated by three co-investigators
(DSR, PIM and VC).Quality assessment
Quality of the studies was examined using a modiﬁed version of
the criteria devised by CAMARADES10. The checklist (Appendix 2)
assessed potential bias judged by the quality of reporting and it
included the following eight criteria: randomisation; allocation
concealment; blinding; evidence of induced OA pain using the
chosen behavioural outcome measure prior to pharmacological
testing; evidence that the animals had structural OA (histological,
macroscopic, microscopic or X-ray); sample size calculation;
statement of conﬂict of interest; and statement of compliance with
animal welfare regulations. Each item was scored as 1 if reported
satisfactorily, and 0 if not (unclear risk of bias). The maximum score
was 8.Data analysis
Categorisation of study characteristics
Each generic drug was categorised as oral NSAID, opioid,
paracetamol, intra-articular corticosteroid injection, topical
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(single dose) or chronic (at least one dose on two or more
consecutive days), and the route as intraperitoneal, oral or sub-
cutaneous. A chemical method to induce OA, intra-articular in-
jection of mono-iodoacetate (MIA), was coded according to the
dose (1, 1, 2 or 3 mg/kg). The timing of outcome measurement
was categorised by weekly intervals to reﬂect the stages of OA
disease progression: Week 1 (under 7 days); Week 2 (days 7e13);
Week 3 (days 14e20); Week 4 (days 21e27); and Week 5 (Day 28
or later) post-induction of the OA. Methods used to measure pain
outcomes were categorised into ﬁve modalities (Table I). The
species were subcategorised according to sex and strain, and
combined sample size for the treatment and the control group was
coded by median-split as 14 or >14 animals. The age and weight
of the animals were not categorised or analysed due to insufﬁcient
reporting in the studies.
Meta-analysis of the analgesic treatment effect
The animal experiments included in this systematic review
tested classes of drugs that have been shown to be effective in
the management of OA pain in man12, and these experiments
were used to investigate study-level moderators presuming pri-
marily positive analgesic treatment effects. Factors associated
with large effect sizes may indicate bias that results in over-
estimation of analgesic treatment effect, and therefore low
speciﬁcity for predicting analgesic agents that will reduce OA
pain in man.
Meta-analysis using the random effect model20 was carried out
in StatsDirect 2.7.8 (StatsDirect, Altrincham, UK). Standardised
mean difference (SMD) and 95% conﬁdence intervals (CIs) were
calculated for each comparison that assessed the analgesic treat-
ment effect of a drug at a speciﬁc dose, using a pain-related
behavioural outcome measure, between drug-and vehicle-treated
rats with knee OA. The outcome measures included in the analysis
were categorised according to the class of drug and positive anal-
gesic treatment effect, i.e., reduction in pain behaviour, was
measured as positive increasing SMDs.
The SMDs and 95% CIs were pooled by disease progression
(Weeks 1e5) and the ﬁve pain modalities (Table I) and presented
in a forest plot. The total sample size and the numbers of studies
and comparisons were counted for each week and modality.
Non-overlap in CIs indicated statistically signiﬁcant differences
and further subgroup analyses were carried out using meta-
regression. Publication bias was examined using a funnel plot
and Egger's test. The Q test and I2 statistics were calculated to
measure the degree of heterogeneity between studies. The Q test
suggests a signiﬁcant level of heterogeneity if statistically sig-
niﬁcant (P < 0.05) whereas the I2 value (0e100%) indicates the
percentage of the heterogeneity across studies that is not due to
chance.
Meta-regression of study-level moderators
Meta-regression20 was used to explain heterogeneity across
comparisons using SMD as the response variable and study
design and quality as explanatory variables. All the independent
variables were coded into dummy variables and included in the
regression model as covariates, apart from the total quality score
which was included as an interval variable. Regression parame-
ters were tested individually for each group of dummies and the
total quality score, and adjusted for the class of drug. Inverse
variance for the meta-regression was calculated in MS Ofﬁce
Excel 2007. Meta-regression was carried out in SPSS21 (IBM,
USA) using random effects metareg21 command which produces
z-tests and P-values for testing the signiﬁcance of regression
coefﬁcients.Avoidance of double-counting
All the comparisons (as per each drug, dose, time point, time to
outcome measurement, and test method) reported in the studies
were treated as separate observations. This introduced a problem of
double-counting as the studies often used one group of animals in
more than one comparison (range 1e54 comparisons). Including
only one observation from each study would have excluded rele-
vant data from the meta-analysis, while pooling of data may have
resulted in a loss of information about the variation in the analgesic
treatment effect. Therefore we pragmatically limited the number of
observations selected for the analysis.
For each drug, both the acute and the chronic administration
were included from each week (weeks 1e5) for each behavioural
pain test. Where analgesic treatment effect was measured at
different doses of the drug, the median dose was chosen (celecoxib
30 mg/kg, diclofenac 30 mg/kg, indomethacin 2 mg/kg, naproxen
10 mg/kg, rofecoxib 10 mg/kg, morphine 3 mg/kg, and tramadol
100 mg/kg). The median dose was chosen assuming that it would
be closest to the optimal dose and most relevant for the accurate
measurement of analgesic treatment effect.
Only one time point was included from each week (day 3, 7, 14,
21, 28 or the closest day after), and the median outcome mea-
surement (1 h time) was chosen over other times. Decision to
differentiate between weekly time points was made assuming that
pain outcomes depend on disease progression6, and that the
analgesic treatment effect may change over time.
Finally, only one set of results was included from repeat tests at
increasing intensities. This concerned one study22 fromwhich only
data using the middle ﬁlament weight (6 g) of the three reported
von Frey tests was included.
This process decreased the number of observations from 246 to
102. The extent of residual double-counting was estimated
assuming that each drug at a speciﬁc dose was tested in a separate
cohort of animals, but that repeat tests were carried out for the
following comparisons: (1) testing one group of animals at different
weekly time points; (2) testing both the acute and chronic
administration of a drug with one group of animals; (3) subjecting
one group of animals to more than one behavioural pain test; and
(4) including one vehicle-treated control group of animals in more
than one comparison.Results
Study selection
A ﬂow diagram in Fig. 1 presents the study selection process.
Characteristics of the ﬁfty studies that met the inclusion criteria are
presented in Table II.
The majority (42/50) of the studies used rat model of OA and
only a few (3, 3 and 2, respectively, of 50) used mice, rabbits or
guinea pigs, and knee was the most commonly investigated joint
(45/50). Thirty-nine studies used a chemical method of induction
which was intra-articular injection of MIA. Eleven studies used
surgical method of induction which included meniscal transection
(5/11), anterior cruciate ligament section (3/11), destabilisation of
the medial meniscus (2/11) and the Hulth model (1/11). The drugs
tested in the studies included NSAIDs (31/50), opioids (16/50),
paracetamol (4/50) or topical NSAID (2/50). The most common pain
modalities reported were static weight bearing (28/50) and
mechanically-evoked pain (15/50), and smaller number of studies
examined grip strength (7/50), movement-evoked pain (6/50) and
thermally-evoked pain (3/50). Individual studies could involve
more than one control group, drug, and pain modality (i.e., the total
for each item may exceed 50).
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treatment effect of drugs with vehicle-treatment in animals with
OA, and meta-analysis was carried out for 102 such comparisons
from 26 studies that investigated a rat model of knee OA. The
following drugs were tested in at least three studies and satisﬁed
our criteria for meta-analysis (Table III): celecoxib (10/26), diclo-
fenac (7/26), morphine (7/26), rofecoxib (4/26), indomethacin (3/
26), naproxen (3/26) and tramadol (3/26). The included drugs were
either NSAIDs or opioids.Characteristics of studies included in the meta-analysis
The characteristics of the 26 studies and 102 comparisons
included in the meta-analysis are summarised in Table III, and the
studies are listed in Table IV. OAwas induced using MIA in 94 of the
102 comparisons, and only eight comparisons used a surgicalFig. 1. Flow diagram of study selection.method of induction. The dose of MIA used to induce OA was 1 mg
(29/102), 2 mg (24/102) or 3 mg (41/102). Most of the compari-
sons used Sprague Dawley (52/102) or Wistar (40/102) rats. The
pain modalities were static weight bearing (46/102), mechanically-
evoked pain (31/102), movement-evoked pain (18/102), grip
strength (5/102), and thermally-evoked pain (2/102). The majority
of the comparisons tested NSAIDs (74/102). The drugs and doses
tested are presented in Table III.Meta-analysis of the analgesic treatment effect
The analgesic treatment effect for all 102 comparisons (pooled
SMD; Appendix 3) was 1.36 (95%CI ¼ 1.15e1.57) and the total
sample size was 1628. The distribution of SMDs was positively
skewed and included some large values for the observed treat-
ment effect. The treatment effect for NSAIDs was signiﬁcantly
lower (pooled SMD 1.16; 95%CI ¼ 0.91e1.40) than for opioids
(pooled SMD 1.90; 95%CI ¼ 1.56e2.23). The pooled SMDs for each
drug class were similar across time (Appendix 4). Pooled analgesic
treatment effects of NSAIDs and opioids by pain modality are
presented in Fig. 2 (forest plots in Appendix 5). Thermally-evoked
pain with only two observations from one study was excludedTable II
Summary of study characteristics in the 50 studies that met the inclusion criteria
Study
characteristic
Sub-groups Number of
studies
Species Rat 42
Mouse 3
Rabbit 3
Guinea pig 2
Joint Knee 45
Facet 2
Shoulder 2
Ankle 1
OA model Chemical (all MIAy) 39
Surgical, of which 11
meniscal transection 5
anterior cruciate ligament section 3
medial meniscus destabilisation 2
Hulth modelz 1
Spontaneous 0
Control group* OA 48
of which vehicle-treated OAx 46
Sham-inducedjj 15
Naïve¶ 12
Drugs tested* NSAID 31
Opioid 16
Paracetamol 4
Topical NSAID 2
Topical capsaicin 0
Intra-articular corticosteroid injection 0
Pain modality* Static weight bearing 28
Mechanically evoked pain 15
Grip strength 7
Movement evoked pain 6
Thermally evoked pain 3
* One study could involve more than one control group, drug and pain modality.
y MIA ¼ Intra-articular injection of mono-iodoacetate.
z Hulth model: anterior and posterior cruciate ligaments, medial collateral liga-
ment and meniscal transaction.
x Vehicle-treated OA¼ animals with OA that receive the vehicle for the delivery of
the drug (such as saline) instead of the drug.
jj Sham-induced ¼ Healthy control animals that receive sham surgery/injections
so that the study can control for the effect of anaesthesia and the invasive procedure
involved in the induction of OA. Sham procedures take place prior to the pharma-
cological study.
¶ Naïve¼Healthy control animals that do not undergo any sham procedures prior
to the pharmacological study.
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strength at 3.96 (2.38e5.55) and lowest for movement-evoked
pain at 0.31 (0.08 to 0.71). Other pain modalities displayed in-
termediate SMDs.
Across the 102 comparisons, the funnel plot (Fig. 3) and Egger's
test (P < 0.001) showed publication bias due to a small number of
studies reporting negative analgesic treatment effects. Both the Q
test (Q ¼ 340.55, P < 0.001) and I2 value (70%, 95% CI ¼ 64e75%)
suggested a signiﬁcant level of heterogeneity, which reﬂects the
diversity of study design among the 102 comparisons.Meta-regression of study-level moderators
Overall, the class of drug, pain modality, route of adminis-
tration and study quality emerged as signiﬁcant explanatoryTable III
Summary of study characteristics in the 26 studies and 102 comparisons included in
the meta-analysis. Each comparison compared a drug-treated group and a vehicle-
treated group of rats with knee OA, and assessed the analgesic treatment effect of a
drug at a speciﬁc dose
Characteristic Sub-groups Number of
studies
Number of
comparisons
Animal model
of OA
MIA* 22 94
1 mg 7 29
2 mg 5 24
3 mg 10 41
Meniscal transection 3 7
Anterior cruciate
ligament section
1 1
Rat strain Sprague Dawley 16 52
Wistar 8 40
Lewis 2 6
Sex of the rats Male 26 102
Female 0 0
Drugs testedz,x NSAID 23 74 Dose mg/kg
Celecoxib 10 38 10e100
Diclofenac 7 17 30
Rofecoxib 4 5 10
Indomethacin 3 6 2e3
Naproxen 3 8 10
Opioid 9 28
Morphine 7 22 1e6
Tramadol 3 6 30e100
Route of
administrationz
Oral 18 64
Subcutaneous 7 34
Intraperitoneal 4 4
Length of
administrationy,z
Acute 22 67
Chronic 8 35
Pain modalityz Static weight bearing 15 46
Mechanically evoked
pain
6 31
Pressure 3 14
von Frey 5 17
Movement evoked pain 3 18
Gait analysis 2 14
Forced ambulation 1 2
Knee ﬂexions and/or
extensions
1 2
Grip strength 5 5
Thermally evoked pain
(acetone cooling test)
1 2
Total 26 studies 102 comparisons
Numbers for the main categories are printed in bold, while the numbers for the sub-
categories are in plain text.
* MIA ¼ Intra-articular injection of mono-iodoacetate.
y Length of administration: acute ¼ one time dose, chronic ¼ at least one dose on
two or more consecutive days.
z One study could involve more than one drug, type of administration and
behavioural pain test.
x The following drugs were tested in fewer than three papers and thus excluded:
etoricoxib, felbinac, ibuprofen, ketoprofen, loxoprofen, meloxicam, nimesulide and
paracetamol.variables in the meta-regression (Table V, Appendix 6). As found
in the meta-analysis, NSAIDs were associated with smaller
analgesic treatment effects (SMDs) than opioids (z ¼ 3.25,
P ¼ 0.001). Grip strength gave larger SMDs than assessment of
static weight bearing (z ¼ 4.60, P < 0.001), mechanically-
evoked pain (z ¼ 3.83, P ¼ 0.001) and movement-evoked pain
(z ¼ 5.23, P < 0.001). Further, the SMDs for mechanically-
evoked pain were larger than for movement-evoked pain
(z ¼ 2.78, P ¼ 0.006). Intraperitoneal route of administration
was associated with higher SMDs than oral and subcutaneous
(z ¼ 3.94, P < 0.001 and z ¼ 3.44, P < 0.001). However,
intraperitoneal route was only used in four studies that all tested
grip strength with 30e38 mg/kg of celecoxib and gave large
SMDs (range 1.73e7.78). Due to the small numbers it is not
possible to investigate whether this route improved the SMDs for
grip strength.
Incomplete reporting limited the assessment of study quality
and its impact on the magnitude of the SMDs. None of the
studies reported sample size calculation or allocation conceal-
ment, and less than half (12/26) reported randomisation and/or
blinding (Table VI). The quality scores varied between 0 and 5
and the average score per study was 3.7 out of 8. Studies that
achieved a higher overall score and studies that presented evi-
dence that the animals had structural OA were associated with
smaller SMDs (z ¼ 3.64, P < 0.001 and z ¼ 2.45, P ¼ 0.014
respectively). No association was found between the SMDs and
the other design features or quality indicators (results not
presented).
Discussion
This review has identiﬁed that study-level moderators and
publication bias may result in an overestimation of analgesic
treatment effect in animal models of OA. Bias towards positive re-
sults increases the likelihood of identifying promising therapies
that fail in clinical trials. In preclinical studies that model pain, such
bias can be deﬁned as low speciﬁcity to predict analgesic agents
that will reduce pain in man. We have identiﬁed three factors e
choice of design, limited study quality and publication bias e that
may contribute to low speciﬁcity and thus failure of clinical
prediction.
Choice of design
Pain modality and drug administration route emerged signiﬁ-
cant in the meta-regression. Variation in SMDs across the ﬁve
modalities may indicate differences in measurement properties
between the pain-related behaviours. Weight bearing evaluates
pain on loading the joint at rest, in contrast to pain behaviour
observed on joint movement. Thermally- and mechanically-
evoked pain tests are used to measure hyperalgesia, an
increased sensitivity to painful stimuli, or allodynia, pain resulting
from a stimulus which would not normally provoke pain. Grip
strength measures muscle strength which may be inhibited by
pain. The various behavioural measures could therefore have
different predictive value for analgesic efﬁcacy in different patient
subgroups, or, within an individual, for different aspects of their
pain experience.
The pooled SMD for grip strength was signiﬁcantly higher
than for the other modalities, suggesting that grip strength may
be highly sensitive for measuring OA pain in rats. Although there
is potential confounding by intraperitoneal route of drug
administration, this is unlikely to explain the high effect sizes
achieved using grip strength tests. Intraperitoneal injection en-
ables faster absorption than oral administration23, but the
Table IV
List of the studies and comparisons included in the meta-analysis and meta-regression
Study No. of
comparisons
Sample size
per group
Experimental/
Control
Model* MIA
mg/kg
Rat
strainy
Generic drug Dose
mg/kg
Routez Date(s) given Test date(s) Behavioural pain test(s)
Ahn 201240 1 10 10 MIA 2 SD Celecoxib 30 O 14 14 Joint compression
Ahn 201240 1 10 10 MIA 2 SD Celecoxib 30 O 14e16 16 Joint compression
Ashraf 201141 4 8 8 MNX N/A L Indomethacin 2 O 11e35 12, 14, 26, 29 Weight bearing
Beyreuther 200742 6 12 12 MIA 3 W Diclofenac 30 SC 3, 7, 14 3, 7, 14 Paw pressure; von Frey
Beyreuther 200742 6 12 12 MIA 3 W Morphine 3 SC 3, 7, 14 3, 7, 14 Paw pressure; von Frey
Bley 200643 1 10 10 MIA 1 W Rofecoxib 10 O 14 14 Weight bearing
Bove 200344 1 4 8 MIA 1 W Naproxen 10 O 14 14 Weight bearing
Bove 200344 1 8 8 MIA 1 W Rofecoxib 10 O 14 14 Weight bearing
Bove 200645 2 8 6e8 MNX N/A L Rofecoxib 10 O 21 21 Weight bearing,
von Frey
Boyce-Rustay 201014 1 12 12 MIA 3 SD Celecoxib 30 IP 20 or later 20 or later Grip force
Castro 200646 1 6 6 ACLT N/A W Indomethacin 2 SC 4e7 4e7 Weight bearing
Combe 200447 1 10 10 MIA 2 SD Morphine 3 SC 14 or later 14 or later Weight bearing
Combe 200447 1 10 10 MIA 2 SD Tramadol 10 SC 14 or later 14 or later Weight bearing
Cowart 201248 1 12 12 MIA 3 SD Diclofenac 30 O 21 21 Grip force
Ferland 201149 16 6 6 MIA 3 SD Celecoxib 30 O 1e28 3, 8, 15, 22 Gait duty cycle/swing
phase/swing speed,
von Frey
Fernihough 200450 5 6 6 MIA 2 W Diclofenac 30 SC 3, 14, 28 3, 14, 28 Paw pressure, von Frey
only on days 14 and 28
Fernihough 200450 5 6 6 MIA 2 W Morphine 6 SC 3, 14, 28 3, 14, 28 Paw pressure, von Frey
only on days 14 and 28
Ferreira-Gomez
201251
2 5 4 MIA 2 W Diclofenac 30 O 3 3 Gait, knee bend test
Ferreira-Gomez
201251
2 5 4 MIA 2 W Morphine 6 SC 3 3 Gait, knee bend test
Fitzpatrick 201152 4 4 9 MIA 3 W Tramadol 100 O 5, 7, 14, 28 5, 7, 14, 28 Weight bearing
Hsieh 2010A53 1 6 6 MIA 3 SD Celecoxib 30 IP 20 20 Grip force
Hsieh 2010B54 1 12 12 MIA 3 SD Celecoxib 30 IP 20 20 Grip force
Ivanavicius 200755 3 6 6 MIA 1 W Celecoxib 10 O 14, 21, 28 14, 21, 28 Weight bearing
Ivanavicius 200755 3 6 6 MIA 1 W Naproxen 10 O 14, 21, 28 14, 21, 28 Weight bearing
Kang 201056 3 10 10 MIA 3 SD Celecoxib 100 O 1e14 4, 7, 14 Weight bearing
Okun 201257 1 8 6 MIA 4.8 SD Diclofenac 30 O 14 14 Weight bearing
Plummer 201358 1 6 6 MNX N/A SD Rofecoxib 10 O 28 28 Weight bearing
Pomonis 200517 1 10 10 MIA 1 SD Celecoxib 30 O 22 22 Weight bearing
Pomonis 200517 1 10 10 MIA 1 SD Celecoxib 30 O 10e22 22 Weight bearing
Pomonis 200517 1 10 10 MIA 1 SD Indomethacin 3 O 22 22 Weight bearing
Pomonis 200517 1 10 10 MIA 1 SD Morphine 3 SC 21 21 Weight bearing
Pulichino 200616 1 19 29 MIA 1 SD Diclofenac 10 O 7 7 Weight bearing
Rashid 201359 4 8 8 MIA 1 SD Celecoxib 38 O Weeks 1, 2, 3, 4 Weeks 1, 2,
3, 4
Weight bearing
Rashid 201359 4 8 8 MIA 1 SD Celecoxib 38 O Weeks 1, 2, 3, 4 Weeks 1, 2,
3, 4
Weight bearing
Rashid 201359 2 8 8 MIA 1 SD Naproxen 50 O Weeks 1, 3 Weeks 1, 3 Weight bearing
Rashid 201359 2 8 8 MIA 1 SD Naproxen 50 O Weeks 1, 3 Weeks 1, 3 Weight bearing
Rashid 201359 1 8 8 MIA 1 SD Morphine 1 O Weeks 1, 2, 3, 4 Weeks 1, 2,
3, 4
Weight bearing
Vonsy 200922 3 7 7 MIA 2 SD Morphine 3 SC 14 14 Cooling hypersensitivity,
forced ambulation,
von Frey
Vonsy 200922 3 7 7 MIA 2 SD Morphine 3 SC 14e18 18 Cooling hypersensitivity,
forced ambulation,
von Frey
Yao 200860 1 6 6 MIA 3 SD Celecoxib 38 IP 20 20 Grip force
Yoshimi 201061 1 8 8 MIA 1 SD Diclofenac 30 O 21 or later 21 or later Weight bearing
Yoshimi 201061 1 8 8 MIA 1 SD Tramadol 10 O 21 or later 21 or later Weight bearing
Total comparisons 102
The highlighted comparisons tested chronic (at least one dose on two or more consecutive days) administration of the analgesic drug.
* MIA ¼ monosodium iodoacetate, ACLT ¼ anterior cruciate ligament transection, MNX ¼ meniscal transection.
y Rat strain: L ¼ Lewis, SD ¼ Sprague Dawley, W ¼ Wistar.
z Route: IP ¼ intraperitoneal, O ¼ oral, SC ¼ subcutaneous.
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Fig. 2. Pooled SMDs and 95% CIs for the analgesic treatment effect of NSAIDs and opioids, by pain modality. Positive increasing SMDs indicate analgesic efﬁcacy. Thermally-evoked
pain with only two observations from one study was excluded from the analysis. One study may involve the testing of more than one pain modality and/or drug. Forest plots for
each subgroup are presented in Appendix 5.
-3 0 3 6 9
1.9
1.4
0.9
0.4
Effect size
Standard error
Fig. 3. Funnel plot for the magnitude of the analgesic treatment effect (n ¼ 102). Test
for publication bias: Egger's test ¼ 5.04 (95% CI ¼ 3.72e6.36) P < 0.0001.
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by the subcutaneous route24,25. Grip strength was developed to
assess the integrity of the neuromuscular system in toxicology
studies, but more recently has been used in animal models of
pain26e28. Our analysis suggests that grip strength deserves
further attention as a sensitive pain behavioural measure in rats,
with potential to reduce the numbers of animals required to
demonstrate efﬁcacy in analgesic studies.
Publication bias and study quality
The distribution of SMDs was positively skewed and included
some large values for positive treatment effects, which
suggests under-reporting of less positive results. Publication bias
may be generated by selective reporting by authors, or journal
editorial policy on concise reporting. Publication of well
Table V
Study-level moderators of the magnitude of the analgesic treatment effect. Full re-
sults are presented in Appendix 6
Overall model (n ¼ 102) B Z P
Individual variables/groups of dummies
Class of drug
NSAID vs opioid 0.80 3.25 0.001
Pain modality*,y
Weight bearing vs grip strength 2.66 4.60 <0.001
Mechanically-evoked pain vs grip strength 2.29 3.83 <0.001
Movement-evoked pain vs grip strength 3.22 5.23 <0.001
Movement-evoked pain vs
mechanically-evoked pain
0.92 2.78 0.006
Route of administration*
Oral vs intraperitoneal 2.55 3.94 <0.001
Subcutaneous vs intraperitoneal 2.36 3.44 <0.001
Study quality sub-components*
Evidence of OA 0.61 2.45 0.014
Overall study quality*
Total quality score 0.34 3.64 <0.001
* Controlled for class of drugs.
y Thermally-evoked pain with only two observations from one study was
excluded from the analysis, n ¼ 100.
Table VI
Number and proportion of publications reporting individual components of the
study quality checklist for the 26 studies included in the meta-analysis, and for the
total 50 studies. The checklist is presented in Appendix 2
Criteria 26 studies in the
meta-analysis
Total of 50
studies
n % n %
Randomisation 12 46 19 38
Allocation concealment 0 0 0 0
Blinding 12 46 18 36
Evidence of induced OA pain 10 39 21 42
Evidence that the animals had OA 13 50 25 50
Sample size calculation 0 0 0 0
Statement regarding potential
conﬂict of interest
3 12 12 24
Statement of compliance with
animal welfare regulations
25 96 46 92
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balanced picture of analgesic efﬁcacy within the scientiﬁc
literature.
Lower study quality was associated with larger SMDs and
potential overestimation of the analgesic treatment effect. Lack of
reported evidence that OA structural change was successfully
induced in the model was strongly associated with larger effect
sizes. Incomplete phenotyping of animals prior to pharmaco-
logical interventions may result in confounding of analgesic ef-
fects by non-OA pathology. Evidence of structural OA is a
pragmatic and relevant measure of study quality that can be used
alongside the traditional checklist items. Indeed, traditional
quality items such as blinding and randomisation were rarely
reported and failed to explain differences in the analgesic
treatment effect.
Caveats of the study
Systematic review and meta-analysis are now well recognised
methodologies permitting robust conclusions in clinical sciences,
but raise speciﬁc issues in preclinical studies. Repeat observations
are typically reported in each preclinical study, and a single con-
trol group is often used in more than one comparison, thereby
reducing animal usage. However, inclusion of multiple observa-
tions per group and per study may introduce bias during meta-
analysis. A further limitation of our work is that preclinical
studies frequently did not report data in numerical format,
necessitating the use of digital ruler software that may result in
measurement errors. We concur with the Animal Research:
Reporting In Vivo Experiments (ARRIVE) guidelines29 which
recommend improved reporting standards in preclinical research.
It is worth noting that we did not assess the predictive value
of individual studies, and that a large analgesic treatment effect
does not mean failure of prediction. Rather, we used a set of
observations that tested NSAIDs and opioids to identify study-
level moderators that may contribute to overestimation of anal-
gesic treatment effect when testing novel compounds. Additionalfactors to those addressed in this review contribute to the se-
lection of preclinical methodologies for testing analgesic efﬁcacy,
including comparability of models to human disease, the
importance of avoiding unnecessary suffering in animals, cost,
and available local expertise. However, preclinical researchers
should pay close attention to aspects of study design, quality and
potential biases in order to maximise the generalisability of their
results.Conclusions
Systematic review and meta-analysis can be used to investigate
sources and impact of bias, and these techniques are gaining
ground in animal laboratory science as shown by recent published
reviews19,30e35 and methods papers11,36e39. Applying such
methods we have identiﬁed study-level moderators e choice of
design, limited study quality and publication bias e that may result
in overestimation of analgesic treatment effect. These moderators
may reduce speciﬁcity for preclinical studies to predict analgesic
agents that will reduce arthritis pain in man. The reviewed data
suggest important publication bias in animal studies, and both re-
searchers and editors should strive to publish negative as well as
positive research ﬁndings. Particular attention to the pain modality,
study quality and quantiﬁcation of OA phenotype is required, both
in the design of new studies, and in interpretation of results. Im-
provements in study design and reporting may increase the po-
tential for preclinical research to predict effects of novel analgesic
treatments in man, thereby reducing the pursuit of potentially
unsuccessful clinical trials, and facilitating translation of effective
novel drugs into clinical practice.Contributors
AKS, DRS, PIM, VC and DAW were involved in the conception
and design of the study. Data were extracted by AKS and validated
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55. meniscectomy.mp.Appendix 1. Search strategy in OVID Medline
Search terms for osteoarthritis (OA)
1. osteoarthritis.mp. or exp Osteoarthritis, Hip/or exp Osteoarthritis/or
exp Osteoarthritis, Spine/or exp Osteoarthritis, Knee/
2. osteoarthrosis.mp.
3. gonarthritis.mp.
4. gonarthrosis.mp.
5. gonitis.mp.
6. coxarthritis.mp.
7. coxarthrosis.mp.
8. coxitis.mp.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
Search terms for nociception
10. pain.mp. or exp Pain/
11. hyperalgesia.mp. or exp Hyperalgesia/
12. hyperalgesic.mp.
13. allodynia.mp.
14. exp Pain Threshold/or exp Pain Measurement/or pain threshold*.mp.
15. exp Nociception/
16. nocicept*.mp.
17. 10 or 11 or 12 or 13 or 14 or 15 or 16
Search terms for small animal models (The Species)
18. rats.mp. or exp Rats/
19. rat.mp.
20. exp Mice/or mice.mp.
21. mouse.mp.
22. exp Guinea Pigs/or guinea pig*.mp.
23. rabbit.mp. or exp Rabbits/
24. rabbit*.mp.
25. 18 or 19 or 20 or 21 or 22 or 23 or 24
Combine OA, nociception and the species
26. 9 and 17 and 25
Search terms for spontaneous models of OA
27. (“DBA/1” or “str/ort” or “c57bl/6” or “C57” or “BALB/c”).mp.
28. dunkin-hartley.mp.
29. hartley guinea pig*.mp.
30. 27 or 28 or 29
Search terms for chemical models of OA
31. iodoacetate*.mp.
32. osmic acid*.mp.
33. thiotepa*.mp.
34. colchicine*.mp.
35. nitrogen mustard*.mp.
36. polyene antibiotic*.mp.
37. (ﬁlipin* or philipine*).mp.
38. vitamin A.mp.
39. Steroid*.mp.
40. corticosteroid*.mp.
41. enzyme*.mp.
42. collagenase*.mp.
43. trypsin*.mp.
56. (cartilage adj8 scariﬁcation*).mp.
57. (osteochondral adj8 (fragment or fracture or chip)).mp.
58. ovariectomi*.mp.
59. 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58
Combine spontaneous or chemical or surgical models of OA
60. 30 or 49 or 59
combine [OA, nociception and the species] and [models of OA]
61. 26 and 60Appendix 2. Checklist for study quality and potential risk of
bias as judged by the quality of reporting. Each item was
scored as 1 if reported satisfactorily, and 0 if not (unclear risk
of bias). Maximum score was 8Risk of bias Criteria Explanation
Selection
bias
1. Randomisation Random assignment of animals
to experimental (treatment) or
control groups
2. Allocation concealment Concealing the allocation sequence
from those assigning animals to
experimental and control groups,
until the moment of assignment.
Detection
bias
3. Blinding Keeping the persons who perform
the experiment, collect data, and
assess outcome unaware of the
treatment allocation.
Other
sources
of bias
4. Evidence of induced
OA pain prior to
pharmacological
study
Timeline showing the effect of the
induced OA on change in
pain-related behavioural outcome
measures over the course of the
experiment
5. Evidence presented
to demonstrate that
the animals had OA
Histological, macroscopic,
microscopic or X-ray evidence
6. Sample size calculation
before start of
experiment
7. Statement regarding
potential conﬂict of
interest
8. Statement of
compliance with
animal welfare
regulations
Appendix 3. Forest plot presenting the SMD (95% CIs)
between drug-and vehicle-treated rats with knee OA
Appendix 4. Pooled SMDs and 95% CIs for the analgesic
treatment effect of NSAIDs and opioids, by Weeks 1e5 post-
induction of OA. Positive increasing SMDs indicate analgesic
efﬁcacy. One study may involve the testing of more than one
drug and weekly time point
Time after OA
induction
Week 1 Week 2 Week 3 Week 4 Week 5
NSAIDs
SMD 1.25 1.06 1.21 1.20 0.84
95% CIs 0.73, 1.77 0.42, 1.69 0.79, 1.63 0.62, 1.79 0.20, 1.49
No. of studies 7 6 12 11 4
No. of comparisons 17 11 21 19 6
Total sample size 254 212 326 310 76
Opioids
SMD 1.94 1.47 1.91 1.74 3.07
95% CIs 1.45, 2.42 0.83, 2.11 1.40, 2.41 0.51, 2.97 0.02, 6.12
No. of studies 5 2 5 2 2
No. of comparisons 7 3 13 2 3
Total sample size 107 61 209 36 37
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Appendix 5. Forest plot of comparisons measuring the analgesic treatment effect of NSAIDs and opioids between drug-treated and
vehicle-treated rats with knee OA, by pain modality. A summary table is presented in Fig. 2. SMD ¼ standardised mean difference,
95% CIs ¼ 95% conﬁdence intervals
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Appendix 6. The impact of study-level moderators on the magnitude of the analgesic treatment effect (n ¼ 102 unless stated
otherwise). All variables (apart from NSAID vs opioid) have been adjusted for the class of drug
Individual variables/groups of dummies B Z P
Class of drug
NSAID vs opioid 0.80 3.25 0.001*
Pain modality (n ¼ 100)y
Weight bearing vs grip strength 2.66 4.60 < 0.001*
Mechanically-evoked pain vs grip strength 2.29 3.83 < 0.001*
Movement-evoked pain vs grip strength 3.22 5.23 < 0.001*
Movement-evoked pain vs
mechanically-evoked pain
0.92 2.78 0.006*
Weight bearing vs mechanically-evoked pain 0.37 1.41 0.157
Weight-bearing vs movement-evoked pain 0.56 1.82 0.068
Timing of the outcome measurement (post-induction of OA): Weeks 1e5
Week 2 vs Week 1 0.29 0.79 0.429
Week 3 vs Week 1 0.06 0.20 0.838
Week 4 vs Week 1 0.12 0.36 0.716
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(continued )
Individual variables/groups of dummies B Z P
Week 5 vs Week 1 0.13 0.30 0.763
Week 3 vs Week 2 0.22 0.66 0.511
Week 4 vs Week 2 0.17 0.45 0.654
Week 5 vs Week 2 0.15 0.32 0.748
Week 4 vs Week 3 0.06 0.19 0.848
Week 5 vs Week 3 0.07 0.17 0.866
Week 5 vs Week 4 0.01 0.03 0.978
Method of induction
MIA vs surgical induction 0.42 1.03 0.302
Dose of MIA (n ¼ 94)z
MIA 2 mg vs MIA 1 mg 0.65 1.90 0.057
MIA 3 mg vs MIA 1 mg 0.07 0.25 0.801
MIA 3 mg vs MIA 2 mg 0.58 1.88 0.060
Rat strain
Wistar vs Sprague Dawley 0.15 0.65 0.513
Lewis vs Sprague Dawley 0.29 0.62 0.536
Lewis vs Wistar 0.44 0.91 0.362
Sample size per comparison
Sample size 14 vs >14 0.07 0.33 0.742
Route of administration
Oral vs intraperitoneal 2.55 3.94 <0.001*
Subcutaneous vs intraperitoneal 2.36 3.44 <0.001*
Oral vs subcutaneous 0.19 0.68 0.499
Administration of the drug
Acute vs chronic 0.15 0.65 0.515
Overall study quality
Total quality score 0.34 3.64 <0.001*
Study quality sub-componentsx
Randomisation to groups 0.50 1.79 0.074
Blinding of outcome assessment 0.37 1.45 0.148
Evidence of induced OA pain prior to
pharmacological study
0.16 0.55 0.580
Evidence presented to demonstrate
that the animals had OA
0.61 2.45 0.014*
Conﬂict of interest statement 0.07 0.16 0.872
Excluded variables: Sex (all animals were male); age and weight (insufﬁcient reporting).
* Values in bold are statistically signiﬁcant at P < 0.05.
y Thermally-evoked pain with only two observations from one study was excluded from the analysis, n ¼ 100.
z Observations that used a surgical method of OA induction were excluded, n ¼ 94.
x None of the studies reported allocation concealment or sample size calculation, and all gave a statement of compliance with animal welfare regulations. These categories
were excluded from the analysis.
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